Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
fda
5
×
indiana blog main
5
×
indiana top stories
national blog main
raleigh-durham blog main
raleigh-durham top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
eli lilly
abeona therapeutics
affordable care act
agios pharmaceuticals
alirocuma
alzheimer's
ameet nathwani
amgen
arches
cancer
clinical trials
What
pharmaceutical
5
×
bio
roundup
american
based
best
continue
crash
debate
drugs
eli
giant
healthcare
industry
kind
nash
new
people
policy
politicians
pressure
scalps
trump’s
u.s
acute
addresses
appetite
approval
bails
black
brand
bread
bridgebio
butter
buyout
cancer
capital
car
cash
causes
Language
unset
Current search:
xconomy.com
×
" indiana blog main "
×
fda
×
pharmaceutical
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More